Primary Job Title Director Primary Organization 
Vatera Healthcare Partners
Gender Male
Investor Type
LinkedIn View on LinkedIn
Mr. Christopher P. Kiritsy co-founded Arisaph Pharmaceuticals, Inc. in 1999 and has been its Chief Executive Officer & President since June 2005. Mr. Kiritsy served as Consultant of Kos Pharmaceuticals Inc. since May 23, 2005. He served as an Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals
Inc., until May 20, 2005. He served as Senior Vice President of Kos Pharmaceuticals Inc.
He played a key operating role in commercializing Kos' two internally developed cholesterol therapies (Niaspan® and Advicor®). In 1999, while serving as Director of Business Planning at Kos Pharmaceuticals, a non-executive officer position, and before Kos Pharmaceuticals conducted business with Triad, Mr. Kiritsy acted as advisor to Mr. Jaharis in connection with his initial investment in Triad. He is a seasoned entrepreneur and possesses 17 years of unique business and technical experience, previously holding senior management positions in R&D and general management, including business development and finance.
He has been Director of Avaxia Biologics, Inc since April 2012. Mr. Kiritsy serves as a Member of the Advisory Board of Vatera Healthcare Partners (also known as Vatera Capital LLC). He has been a Director of Arisaph Pharmaceuticals, Inc. since 1999. He has been a member of the Board of Directors of Triad since 1999. He served as Associate Director of Product Development at the Institute of Molecular Biology, where he co-authored several publications in scientific journals.
Mr. Kiritsy received an A.B. from Bowdoin College in Biology and an M.B.A. from Boston University.
